Readystate Asset Management LP Acquires Shares of 121,000 NewAmsterdam Pharma (NASDAQ:NAMS)

Readystate Asset Management LP bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 121,000 shares of the company’s stock, valued at approximately $2,009,000. Readystate Asset Management LP owned approximately 0.13% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Cinctive Capital Management LP boosted its holdings in shares of NewAmsterdam Pharma by 77.7% during the 3rd quarter. Cinctive Capital Management LP now owns 66,571 shares of the company’s stock valued at $1,105,000 after acquiring an additional 29,115 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in shares of NewAmsterdam Pharma by 19.5% in the third quarter. ArrowMark Colorado Holdings LLC now owns 354,975 shares of the company’s stock worth $5,893,000 after acquiring an additional 57,806 shares during the period. Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma during the third quarter valued at approximately $128,000. Finally, Walleye Capital LLC bought a new position in NewAmsterdam Pharma during the third quarter valued at approximately $779,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,803 shares of company stock worth $1,755,307 over the last three months. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Down 8.6 %

NASDAQ NAMS opened at $18.27 on Thursday. The stock’s 50-day moving average price is $19.72 and its 200-day moving average price is $18.56. NewAmsterdam Pharma has a 52 week low of $8.90 and a 52 week high of $26.35.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NAMS shares. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, November 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.